ACE and Encephalopathy: It is reasonable to speculate that ACE drugs may be associated with the treatment of COVID-19-related encephalopathy, and it has also been confirmed that the SARS-CoV-2 virus may pass through the infection pathway of the olfactory bulb, and the destruction of the hippocampus and amygdala may lead to the occurrence and development of cognitive impairment in patients (Guedj et al., 2021).